SMTI Sanara MedTech (SMTI) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0000714256
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
48
13F, latest reported quarter
Sanara MedTech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Sanara MedTech Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Nov 4, 2022.
- The trade is 1.1% of the 36,270 shares held after it.
- No other insider sold within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Fleming Zachary B. sold about $13.8K of SMTI on Nov 8, 2022; 48 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Nov 2, 2022.
- The trade is 1.5% of the 36,687 shares held after it.
- No other insider sold within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Fleming Zachary B. sold about $18.6K of SMTI on Nov 4, 2022; 48 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jul 6, 2022.
- The trade is 0.1% of the 37,250 shares held after it.
- No other insider sold within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Fleming Zachary B. sold about $660 of SMTI on Nov 2, 2022; 48 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 17, 2022.
- The trade is 1.8% of the 18,550 shares held after it.
- No other insider sold within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres. - Strategic Partnerships Bowman Shawn M. sold about $9.7K of SMTI on Sep 22, 2022; 48 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 17, 2022.
- The trade is 3.5% of the 18,890 shares held after it.
- No other insider sold within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres. - Strategic Partnerships Bowman Shawn M. sold about $18.2K of SMTI on Sep 22, 2022; 48 funds added in the latest 13F quarter.18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
48 funds bought in last quarter
below 59% of Medical Devices
Revenue
+19.0% year over year
more than 70% of Medical Devices
Margin
-36.4% net margin
below 62% of Medical Devices
Buybacks
no share repurchases reported
Short interest
9.9% of the float short (float per yahoo 2026-10-27) · 1.8 days to cover · settled 2026-10-15
more than 57% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SMTI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+9.8%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SMTI: institutional holders (13F)
13F holdings, latest reported quarter
248,827 sh
$5.9M
194,897 sh
$4.6M
130,995 sh
$3.1M
129,452 sh
$3.1M
112,207 sh
$2.6M
Congress trades in SMTI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SMTI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SMTI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Columbia Integrated Small Cap Growth Fund
$97.7K position · as of 2026-05-31
0.3%
Small Company Growth Portfolio
$50.4K position · as of 2026-06-30
0.2%
U.S. Small Cap Equity Fund
$373.7K position · as of 2026-07-31
0.0%
Venerable US Small Cap Fund
$55.3K position · as of 2026-06-30
0.0%
GuideMark Small/Mid Cap Core Fund
$20.3K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$264.9K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 48 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SMTI financials
Revenue growth
+19.0%
XBRL, annual
Net margin
-36.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$109.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SMTI
| FY Dec 2025 | $103.1M |
| FY Dec 2024 | $86.7M |
| FY Dec 2023 | $65.0M |
| FY Dec 2022 | $45.8M |
| FY Dec 2021 | n/a |
| Jun 2026 | $28.1M |
| Mar 2026 | $27.8M |
| Dec 2025 | $27.5M |
| Sep 2025 | $26.3M |
| Jun 2025 | $25.8M |
| Mar 2025 | $23.4M |
| Dec 2024 | $26.3M |
| Sep 2024 | $21.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+39.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SMTI
| FY Dec 2025 | +36.4% |
| FY Dec 2024 | +11.2% |
| FY Dec 2023 | +6.6% |
| FY Dec 2022 | -17.3% |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.6% |
| Mar 2026 | +1.7% |
| Dec 2025 | +266.9% |
| Sep 2025 | -115.5% |
| Jun 2025 | -7.8% |
| Mar 2025 | -15.1% |
| Dec 2024 | +67.6% |
| Sep 2024 | -13.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SMTI
| FY Dec 2025 | $2.2M |
| FY Dec 2024 | -$229.6K |
| FY Dec 2023 | -$3.5M |
| FY Dec 2022 | -$5.7M |
| FY Dec 2021 | -$5.0M |
| Jun 2026 | $2.0M |
| Mar 2026 | -$2.5M |
| Dec 2025 | $3.9M |
| Sep 2025 | $1.1M |
| Jun 2025 | $902.7K |
| Mar 2025 | -$3.7M |
| Dec 2024 | $859.9K |
| Sep 2024 | $2.0M |
At each fiscal year end
Single quarter
Debt to equity
6.23x
long-term 2026-06-30 plus current 2024-03-31 (27 months older than the period end); equity 2026-06-30
Debt to equity SMTI
| FY Dec 2025 | 8.25x |
| FY Dec 2024 | 0.85x |
| FY Dec 2023 | 0.22x |
| FY Dec 2022 | 0.01x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | 6.23x |
| Mar 2026 | 7.00x |
| Dec 2025 | 8.25x |
| Sep 2025 | 7.82x |
| Jun 2025 | 1.33x |
| Mar 2025 | 1.27x |
| Dec 2024 | 0.85x |
| Sep 2024 | 0.83x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.12x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-03-31 (27 months older than the period end)
Cash flow to debt SMTI
| FY Dec 2025 | 0.14x |
| FY Dec 2024 | -0.00x |
| FY Dec 2023 | -0.33x |
| FY Dec 2022 | -9.53x |
| FY Dec 2021 | -8.26x |
| Jun 2026 | 0.12x |
| Mar 2026 | 0.13x |
| Dec 2025 | 0.14x |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.08x |
| Mar 2025 | -0.01x |
| Dec 2024 | -0.00x |
| Sep 2024 | -0.05x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+198.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SMTI
| FY Dec 2025 | +165.7% |
| FY Dec 2024 | +22.9% |
| FY Dec 2023 | +9.9% |
| FY Dec 2022 | -21.9% |
| FY Dec 2021 | -43.1% |
| Jun 2026 | +198.9% |
| Mar 2026 | +190.2% |
| Dec 2025 | +165.7% |
| Sep 2025 | -79.1% |
| Jun 2025 | +24.4% |
| Mar 2025 | +19.8% |
| Dec 2024 | +22.9% |
| Sep 2024 | +0.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+51.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SMTI
| FY Dec 2025 | +46.7% |
| FY Dec 2024 | +11.9% |
| FY Dec 2023 | +6.4% |
| FY Dec 2022 | -16.3% |
| FY Dec 2021 | -34.3% |
| Jun 2026 | +51.3% |
| Mar 2026 | +50.2% |
| Dec 2025 | +46.7% |
| Sep 2025 | -22.8% |
| Jun 2025 | +10.9% |
| Mar 2025 | +9.4% |
| Dec 2024 | +11.9% |
| Sep 2024 | +0.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SMTI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+12.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SMTI
| FY Dec 2025 | +11.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -7.8% |
| FY Dec 2022 | -31.8% |
| FY Dec 2021 | -40.2% |
| Jun 2026 | +12.0% |
| Mar 2026 | +13.2% |
| Dec 2025 | +11.5% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SMTI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$337.4M
market value at close 2026-10-26 on 2026-08-07 shares, plus long-term 2026-06-30 plus current 2024-03-31 (27 months older than the period end), minus cash 2026-06-30
Enterprise value SMTI
| FY Dec 2025 | $241.0M |
| FY Dec 2024 | $308.0M |
| FY Dec 2023 | $355.5M |
| FY Dec 2022 | $369.4M |
| FY Dec 2021 | $207.5M |
| Jun 2026 | $250.2M |
| Mar 2026 | $193.1M |
| Dec 2025 | $241.0M |
| Sep 2025 | $315.6M |
| Jun 2025 | $282.6M |
| Mar 2025 | $300.5M |
| Dec 2024 | $308.0M |
| Sep 2024 | $281.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield SMTI
| FY Dec 2025 | +1.0% |
| FY Dec 2024 | -0.1% |
| FY Dec 2023 | -1.0% |
| FY Dec 2022 | -1.5% |
| FY Dec 2021 | -2.2% |
| Jun 2026 | +2.1% |
| Mar 2026 | +2.1% |
| Dec 2025 | +1.0% |
| Sep 2025 | -0.3% |
| Jun 2025 | +0.0% |
| Mar 2025 | -0.8% |
| Dec 2024 | -0.1% |
| Sep 2024 | -0.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SMTI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $103.1M | $86.7M | $65.0M | $45.8M |
| Gross profit | $95.6M | $78.5M | $57.1M | $39.5M |
| Operating income | $7.3M | $1.3M | -$4.2M | -$12.5M |
| Net income | $37.6M | $9.7M | $4.3M | -$7.9M |
| EPS (diluted) | -4.36 | -1.14 | -0.52 | -1.00 |
| Operating cash flow | $6.8M | -$23.8K | -$3.2M | -$5.6M |
| Cash | $16.6M | $15.9M | $5.1M | $9.0M |
| Long-term debt | $46.0M | $30.7M | $9.1M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
SMTI Stock Sonar score 5/7 axes
Find similar shapesCompareSMTI ranks highest on profitability (94th percentile) and growth (70th), and lowest on financial health (32nd), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
